Prognostic significance of molecular detection of minimal residual disease in childhood acute lymphoblastic leukemia

儿童急性淋巴细胞白血病微小残留病分子检测的预后意义

• 批准号: 08670875
• 负责人: HORIBE Keizo
• 金额: $ 1.41万
• 依托单位: Nagoya University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1996
• 资助国家: 日本
• 起止时间: 1996 至 1998
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08670875/
• 关键词: Acute lymphoblastic leukemia; Minimal residual disease; Polymerase chain reaction; Immunoglobulin heavy chain; TEL-AML1; BCR-ABL; E2A-PBX1; Prognostic factor; CDRIII; t(12;21); t(1;19); t(9;22)

Detection and clinical assessment of minimal residual disease (MRD) of acute lymphoblastic leukemia (ALL) were performed for 50 children with ALL diagnosed and treated between 1987 to 1997 in Nagoya University Hospital and its affiliated hospitals. E2A-PBX1, BCR-ABL and TEL-AML1 were detected by reverse transcription polymerase chain reaction (RT-PCR) method for leukemia with t (l ; 19), t (9 ; 22) or t (12 ; 21). In 26 cases of leukemia without detectable specific traslocation MRD was assessed by PCR using unique sequence of complementality determining region III of immunoglobulin heavy chain (IgH CDR III).Bone marrow samples at 1 to 3 months after starting chemotherapy were available in 19 patients with specific fusion gene. Two of 16 patients negative for the MRD at that time relapsed later, while all the 3 patients positive for the MRD at that time relapsed later. Bone marrow samples at 1 to 3 months after starting chemotherapy were analyzed in 23 patients using specific probe for IgH CDR III.Five of 19 patients negative for the MRD at that time relapsed later, while all the 3 patients positive for the MRD at that time relapsed later. Combining these data, prognosis for patients with positive MRD at 1 to 3 months after starting chemotherapy was significantly worse than that for patients with negative MRD at that time.Now we are going to collect the cases with uniform chemotherapy to analyze the MRD and to establish its usefulness for stratifying the treatment for childhood ALL in Japan.

在1987年至1997年间，对50名诊断和治疗的儿童进行了急性淋巴细胞白血病（ALL）的最小残留疾病（MRD）的检测和临床评估。通过T（L; 19），T（9; 22）或T（12; 21），通过逆转录聚合酶链反应（RT-PCR）方法检测到E2A-PBX1，BCR-ABL和TEL-AML1。在26例没有检测到的特异性traslation的白血病中，通过PCR评估了使用独特的互补性序列确定免疫球蛋白重链的III区域III（IGH CDR III）。在开始化学治疗后1至3个月，在19例特定融合基因的患者中可用。当时16例MRD患者中有2例复发，而当时所有3例MRD呈阳性，以后复发。使用IGH CDR III的特异性探针对23名患者进行了骨髓样品在开始化疗后的1至3个月。结合这些数据，开始化学疗法后1至3个月的MRD阳性患者的预后明显差于当时MRD阴性患者的预后。